Key facts
- It has raised $8.4M; the latest was Seed Round ($8.4M) in Sep 2025.
- Notable investors include CAS Star, Legend Capital, SJ Jiacheng Investment Management, Shanghai Jiao Tong University Foundation, Hongfeng Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for DeliNova Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for DeliNova Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeliNova Therapeutics
Developer of a T-cell targeted therapy system designed to precisely generate CAR-T cells in vivo for hematologic malignancies, autoimmune diseases, and chronic conditions. The company offers engineered viral vector modifications and a multi-dimensional delivery system, enabling patients and clinical researchers the ability to access targeted, efficient, and safe cellular therapies.
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
DeliNova Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeliNova Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeliNova Therapeutics in its N-PORT filings yet. We sweep new filings monthly.